Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Paediatric Vaccine Market Overview for 2023 to 2033

The paediatric vaccine market valuation is US$ 54,130.1 million in 2023. The market is predicted to grow at a remarkable CAGR of 13.1% to reach a valuation of US$ 184,706.7 million by 2033. Thus, it showcases that the paediatric vaccine market is due for significant growth over the coming years.

Production and Distribution Analysis in the Paediatric Vaccine Market

  • The population is not only aware of the risks possessed by diseases like measles, influenza, and polio but also of the importance of warding them off early, thus generating the demand for infant vaccines.
  • The increase in the population, resulting in a booming number of births, aids the paediatric vaccine market as parents seek to safeguard their children and mothers with the help of paediatric vaccines.
  • The eruption of the pandemic changed the focus of the paediatric vaccine producers as they sought to address the looming threat while giving some short shrift to other paediatric vaccines. The paediatric vaccine market is back in the swing of things as vaccine-approval levels are approaching pre-pandemic levels again in the United States.
  • The high cost associated with developing and maintaining vaccines is a challenge for paediatric vaccine manufacturers.
  • The widespread acceptance of paediatric vaccines is augmented by support from governments all over the world, who are launching schemes and adopting policies beneficial to the paediatric vaccine market.
Attributes Details
Paediatric Vaccine Market Value for 2023 US$ 54,130.1 million
Projected Market Value for 2033 US$ 184,706.7 million
Value-based CAGR for 2023 to 2033 13.1%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Historical Performance Compared to Demand Outlook in Paediatric Vaccine Market

The paediatric vaccine market grew at a rate of 9.7% during the historical period from 2017 to 2022. Increasing awareness about vaccines, the development of vaccines for children, the rising rate of approval for vaccines, and other factors are all suggested to contribute to the market's rapid growth.

Diseases that attack weakened immune systems, such as Rubella, Hepatitis A, and Hepatitis B, continue to pose threats to children. The demand for paediatric vaccines will continue unabated over the forecast period due to the prevalence of these diseases.

Historical CAGR 9.7%
Forecast CAGR 13.1%

Short-term Analysis of Paediatric Vaccine Market from 2017 to 2022

The arrival of the pandemic resulted in a growing demand for paediatric vaccines, which greatly boosted the market. The paediatric vaccine market expanded to US$ 48,816.7 million in 2022.

The pandemic also had a negative impact on the paediatric market. While the Covid-19 vaccine helped the market, other paediatric vaccines experienced lower demand. The Covid-19 vaccines were also not suitable for children in the initial stages, losing out on a huge section of the market. However, the pandemic reinforced the need for proper preventative care in the minds of the people.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Long-term Analysis of Paediatric Vaccine Market from 2023 to 2033

The paediatric vaccine market is expected to grow at a robust rate of 13.1% CAGR over the forecast period. By 2033, the market is predicted to reach US$ 184,706.7 million.

Innovations with the help of technology are predicted to drive the market for paediatric vaccines. Gene vaccines are developed with the help of new technology, infusing DNA and RNA to combat diseases. Gene vaccines have found acceptance during the historical period, and their growth is expected to continue over the forecast period.

The rollout of vaccines for COVID-19 during the historical period initially excluded children from the list of beneficiaries. However, vaccines are being tested and approved for use on children, and thus the paediatric market is able to target a big section of the population.

While monovalent vaccines continue to enjoy a major share of the market, there has been a growing demand for bivalent or combination vaccines. Combination vaccines combine the effects of two vaccines in one go and are thus recognized to save people’s time. As the number of vaccines grows, combination vaccines are also expected to increase in popularity due to their multi-effectiveness.

Key Trends Influencing Paediatric Vaccines Market

  • Financial support from both private and public institutions is driving the market’s expansion.
  • There is a growing focus on making paediatric vaccines available to all, and thus, there is a growing trend of making them cheap and even free in some cases.
  • The protection of children from diseases continues to be a priority, and many vaccines are being developed to combat these diseases. Examples include the rotavirus vaccine, chickenpox vaccine, and the mumps vaccine.
  • There are various campaigns focusing on creating awareness about vaccines related to measles and rubella in infants and pregnant women, which are propelling sales of paediatric vaccines.
  • Difficulties prevail in delivering vaccines to countries that do not fall under the developed umbrella. Paediatric vaccine suppliers are also trying to reach customers in these countries.
  • Companies producing paediatric vaccines are collaborating with the likes of health institutions, hospitals, and other players in the market to develop and distribute vaccines.
  • The development of novel vaccines with the help of superlative research methodologies and advancement in science is another trend in the paediatric vaccine market.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Comparative View of Adjacent Markets

The section provides a comparative analysis of the paediatric vaccine market along with two adjacent markets—the vaccine and veterinary vaccine markets.

The table below highlights the growth rates as well as the forecasted values of all markets. The key trends and growth factors in the market are also displayed. Increasing vaccine awareness is a common factor driving growth in all three markets. The continuous advancements in medical sciences also aid the development of all three markets.

Paediatric Vaccine Market:

Attributes Paediatric Vaccine Market
Value-based CAGR (2023 to 2033) 13.1%
Projected Market Value (2033) US$ 184,706.7 million
Market Trends
  • Financial support from governments and private institutions
  • Collaborations between paediatric vaccine suppliers and others in the health industry
Growth Factors
  • The increasing demand for paediatric vaccines in the wake of risks from several diseases
  • Widespread campaigns on the benefits of paediatric vaccines.

Vaccines Market:

Attributes Vaccines Market
Value-based CAGR (2023 to 2033) 6.6%
Projected Market Value (2033) US$ 80.8 billion
Market Trends
  • Making vaccines available in all corners of the world
  • The development of novel vaccines
Restraints
  • The high cost of storing vaccines
Growth Factors
  • Innovations in technology are fueling the development of vaccines that are highly effective
  • Increasing awareness of diseases that attack the weak immune systems of children

Veterinary Vaccines Market:

Attributes Veterinary Vaccines Market
Value-based CAGR (2023 to 2033) 6.2%
Projected Market Value (2033) US$ 20.82 billion
Market Trends
  • Pet adoption is increasing worldwide
Restraints
  • Lack of awareness in some sections of pet owners about veterinary vaccines
Growth Factors
  • Increased focus on pet care and health

Category-wise Outlook

The paediatric vaccine market can be divided into the following segments: indication, technology, vaccine type, and end users. Shedding light on these segments is useful in determining the nature of the products and users of the vaccines. These insights also shed light on the preferences of users and manufacturers in the paediatric vaccine market.

Pneumococcal Vaccines Lead the Market by Indication

The pneumococcal vaccine is the most represented of the vaccines by indication. It enjoyed a 32.5% share in the global market in 2022, up from 31.9% in 2021.

The pneumococcal vaccine is recommended to be given to children by no less an authority than the World Health Organization (WHO). The use of pneumococcal vaccine can help prevent cases of pneumonia, meningitis, and sepsis. Thus, the pneumococcal vaccine is in high demand.

The pneumococcal vaccine is expected to grow rapidly over the forecast period. As efforts are being expanded toward shielding children from harmful diseases, the value and demand of pneumococcal vaccines are experiencing an upward trajectory.

Attributes Details
Top Indication Pneumococcal Vaccine
Market Share in 2022 32.5%

Conjugate Vaccines: the Most Prevalent Technology Used in Vaccines

Conjugate vaccines make up the highest market share in terms of technology in the paediatric vaccines market. In 2022, they made up 32.8 % of the market share, up from 32% in 2021.

Paediatric vaccine producers rely on conjugate vaccines. They have a track record of being effective, like the Hib conjugate vaccine, which has fought meningitis convincingly. Another example is the typhoid conjugate vaccine, which has proven to reduce the risk of typhoid fever and is WHO-recommended. Conjugate vaccines are thus expected to grow rapidly over the forecast period.

Attributes Details
Top Technology Conjugate Vaccines
Market Share in 2022 32.8%

Monovalent Vaccines Dominate the Market by Vaccine Type

Monovalent vaccines are more popular than multivalent vaccines. They held a share of 73.6 % of the market in 2022.

Monovalent vaccines have historically been the most produced of all vaccines. Their growth is expected to continue over the forecast period. Monovalent vaccine shielding against mumps, rubella, and COVID-19 is predicted to be higher in demand over the projected period. However, multivalent vaccines are also rising. Quadrivalent vaccines are used against the threat of influenza, while new bivalent vaccines have been approved to combat COVID-19.

Attributes Details
Top Type Monovalent Vaccine
Market Share in 2022 73.6%

Institutional Health Centres Make Up the Majority of End-use Sector

Institutional health centres are the most common end-use sector for paediatric vaccines. They enjoyed a significant share of the market in 2022, taking up 72.9% of the share, up from 72.3% in 2021.

Institutional health centres have qualified staff for the administration of paediatric vaccines and are trusted institutions. They also have the support of the government.

Attributes Details
Top End-use Sector Institutional health centers
Market Share in 2022 72.9%

Country-Wise Analysis

In the paediatric vaccine market, North America and Europe continue to lead the market share. In 2022, North America held 24.3% of the market share, while Europe held sway over 26.1%.

The USA is the leading market in North America. It is poised to continue its positive upward trajectory over the forecast period. In Europe, meanwhile, the United Kingdom market is expected to grow at a rapid rate.

Some of the highest growth rates are predicted for the Asia-Pacific. The Chinese and Indian paediatric vaccine markets are expected to boom during the forecast period. The high population in these countries is a significant factor contributing to the rising demand for vaccines.

Countries Market Share in 2022
United States 17.9%
China 19.6%
India 19.2%
United Kingdom 16.1%
Australia 9.4%

Improving Healthcare Facilities Bolsters the Market in the United States

The United States continues to hold the largest market share in the North American market. In the overall paediatric vaccines market, the United States held a market share of 17.9% in 2022.

Healthcare facilities have improved drastically, thus providing better avenues for the distribution of paediatric vaccines. There has also been a growing consciousness among the people of the importance of vaccinations. People are aware of the risks posed to children due to various diseases and are thus willing to resort to vaccines to ward them off. There has also been an increased investment in research and development, which is aiding the cause of paediatric vaccines in the United States.

High Number of Paediatric Patients Drive the Market in China

China experienced the effects of Covid-19 severely. Thus, there is a high volume of paediatric patients. In these circumstances, there is a growing demand for paediatric vaccines. In addition to Covid-19, threats of meningitis, diphtheria, pertussis, and tetanus are also present. This is leading to the rising demand for vaccines like the meningococcal vaccine and the DTaP vaccine.

China’s paediatric vaccine market is expected to soar during the forecast period. It held a 19.6% share of the global market in 2022.

India’s Increasing Paediatric Population Fueling Demand for Paediatric Vaccines

There is also a high volume of paediatric patients in India. As the population is booming, the number of people at risk of diseases is also increasing. Thus, the paediatric vaccine market is being propelled by the rising number of childbirths in India.

The Indian market held a share of 19.2% of the global market in 2022. Leading campaigns by the government are helping the paediatric vaccine market in India. There is a raised acknowledgment of the need for paediatric vaccines, and the market is expected to grow at a substantial rate over the forecast period.

Paediatric Vaccine Initiatives Aid the Market in the United Kingdom

The United Kingdom market is another market where campaigns have played a key role. Initiatives have been taken to increase immunization among the people. The government has launched programs to increase the number of vaccinated children.

The United Kingdom paediatric vaccine market held a share of 16.1% of the global market in 2022. The steps taken by the health authorities in the United Kingdom will drive the market growth during the projected period.

Focus on Immunization of the Paediatric Population in Australia

In the Australian market, paediatric vaccines are in demand as there is fear over the outbreak of diseases. Steps have been taken to make the paediatric population more immunized through vaccines.

The Australian paediatric vaccine market held a share of 9.4% of the global market in 2022. Some of the diseases the Australian people want paediatric vaccines for are COVID-19, Tetanus, and Hepatitis B.

Competitive Landscape in the Paediatric Vaccine Market

The paediatric vaccine suppliers are increasingly leveraging the benefits of collaborations. Partnerships with healthcare institutions, mergers with other manufacturers in the market, acquisitions, and collaborative strategies are some of the strategies adopted by paediatric vaccine suppliers.

The paediatric vaccines market does not feature manufacturers that are highly dominant. Instead, the market is fragmented, with several key players enjoying their share of the pie. The producers of paediatric vaccines are also receiving increasing approvals from health regulators to distribute their vaccines.

Recent Developments in the Paediatric Vaccine Market

  • On June 30, 2023, SK Bioscience Ltd. and Sanofi Pasteur SA reported positive data from their 21-valent pneumococcal conjugate vaccine (PCV) vaccine study.
  • In May 2023, the FDA approved vaccines from companies GSK plc and Pfizer Inc. for respiratory syncytial virus (RSV) treatment. These are the first vaccines approved by the FDA for RSV treatment. Meissa Vaccines Inc. has also reported positive results from trials of its RSV vaccine.
  • On 31 August 2022, Pfizer Inc and BioNTech SE announced that the FDA had approved their Covid-19 vaccine booster dose for people of 12 years or older.
  • In June 2022, GlaxoSmithKline Plc announced that its vaccine for the prevention of measles, mumps, and rubella in people over the age of one year got approval from the FDA.

Key Companies in the Paediatric Vaccine Market

  • GlaxoSmithKline Plc
  • Merck & Co. Inc
  • Pfizer Inc.
  • Sanofi SA
  • Panacea Biotec
  • Zydus Cadila
  • Emergent BioSolutions Inc
  • Serum Institute of India Pvt. Ltd.
  • Bharat Biotech and Indian Immunological
  • Catalent Inc
  • Robinson Pharma Inc.
  • Hunan Er-Kang Pharmaceutical Co. Ltd.
  • Procaps
  • CAPTEK Softgel International Inc
  • Softcaps Fuji Capsule Co. Ltd.
  • Aenova Holding GmbH
  • Sirio Pharma Co. Ltd.
  • Bahrain Pharma
  • Sinovac Biotech Ltd
  • AstraZeneca Plc
  • Meissa Vaccines Inc

Key segments

By Indication:

  • Pneumococcal Conjugate Vaccine
  • DTP Vaccine
  • Influenza
  • Meningococcal Vaccine
  • Polio Vaccine
  • Rotavirus Vaccine
  • MMR Vaccine
  • Varicella Virus Vaccine

By Technology:

  • Live or Attenuated Vaccine
  • Inactivated or Killed Vaccine
  • Toxoid Vaccine
  • Conjugate Vaccine
  • Subunit Vaccine
  • Recombinant Vector Vaccine

By Vaccine:

  • Monovalent Vaccines
  • Multivalent Vaccines

By End-use Sector:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Institutional Health Centres

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

How is the Paediatric Vaccine Market Expected to Evolve During the Forecast Period?

The paediatric vaccine market is projected to grow at a rate of 13.1% through 2033.

Who are the Prominent Companies in the Paediatric Vaccine Market?

Pfizer Inc., GlaxoSmithKline Plc, and Merck & Co. Inc. are some of the prominent companies in the market.

What will be the Market Value for Paediatric Vaccines by 2033?

The market is predicted to reach a valuation of US $ 184,706.7 million by 2033.

Which is the Leading Vaccine Type by Indication?

The pneumococcal vaccine is the leading vaccine type by indication.

What is Driving the Demand for Paediatric Vaccines?

Rising health awareness among the people is the major factor driving the demand for paediatric vaccines.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Product Life Cycle Analysis

    3.5. Supply Chain Analysis

        3.5.1. Supply Side Participants and their Roles

            3.5.1.1. Producers

            3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)

            3.5.1.3. Wholesalers and Distributors

        3.5.2. Value Added and Value Created at Node in the Supply Chain

        3.5.3. List of Raw Material Suppliers

        3.5.4. List of Existing and Potential Buyer’s

    3.6. Investment Feasibility Matrix

    3.7. Value Chain Analysis

        3.7.1. Profit Margin Analysis

        3.7.2. Wholesalers and Distributors

        3.7.3. Retailers

    3.8. PESTLE and Porter’s Analysis

    3.9. Regulatory Landscape

        3.9.1. By Key Regions

        3.9.2. By Key Countries

    3.10. Regional Parent Market Outlook

    3.11. Production and Consumption Statistics

    3.12. Import and Export Statistics

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Indication, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Indication, 2023 to 2033

        5.3.1. Pneumococcal Conjugate Vaccine

        5.3.2. DTP Vaccine

        5.3.3. Influenza

        5.3.4. Meningococcal Vaccine

        5.3.5. Polio Vaccine

        5.3.6. Rotavirus Vaccine

        5.3.7. MMR Vaccine

        5.3.8. Varicella Virus Vaccine

    5.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technology

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Technology, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Technology, 2023 to 2033

        6.3.1. Live or Attenuated Vaccine

        6.3.2. Inactivated or Killed Vaccine

        6.3.3. Toxoid Vaccine

        6.3.4. Conjugate Vaccine

        6.3.5. Subunit Vaccine

        6.3.6. Recombinant Vector Vaccine

    6.4. Y-o-Y Growth Trend Analysis By Technology, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Technology, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Vaccine

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Vaccine, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Vaccine, 2023 to 2033

        7.3.1. Monovalent Vaccines

        7.3.2. Multivalent Vaccines

    7.4. Y-o-Y Growth Trend Analysis By Vaccine, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Vaccine, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By End User, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By End User, 2023 to 2033

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Institutional Health Centers

    8.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Western Europe

        9.3.4. Eastern Europe

        9.3.5. South Asia and Pacific

        9.3.6. East Asia

        9.3.7. Middle East and Africa

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. U.S.

            10.2.1.2. Canada

        10.2.2. By Indication

        10.2.3. By Technology

        10.2.4. By Vaccine

        10.2.5. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Indication

        10.3.3. By Technology

        10.3.4. By Vaccine

        10.3.5. By End User

    10.4. Key Takeaways

11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Indication

        11.2.3. By Technology

        11.2.4. By Vaccine

        11.2.5. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Indication

        11.3.3. By Technology

        11.3.4. By Vaccine

        11.3.5. By End User

    11.4. Key Takeaways

12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. U.K.

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Western Europe

        12.2.2. By Indication

        12.2.3. By Technology

        12.2.4. By Vaccine

        12.2.5. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Indication

        12.3.3. By Technology

        12.3.4. By Vaccine

        12.3.5. By End User

    12.4. Key Takeaways

13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Poland

            13.2.1.2. Russia

            13.2.1.3. Czech Republic

            13.2.1.4. Romania

            13.2.1.5. Rest of Eastern Europe

        13.2.2. By Indication

        13.2.3. By Technology

        13.2.4. By Vaccine

        13.2.5. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Indication

        13.3.3. By Technology

        13.3.4. By Vaccine

        13.3.5. By End User

    13.4. Key Takeaways

14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. India

            14.2.1.2. Bangladesh

            14.2.1.3. Australia

            14.2.1.4. New Zealand

            14.2.1.5. Rest of South Asia and Pacific

        14.2.2. By Indication

        14.2.3. By Technology

        14.2.4. By Vaccine

        14.2.5. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Indication

        14.3.3. By Technology

        14.3.4. By Vaccine

        14.3.5. By End User

    14.4. Key Takeaways

15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. China

            15.2.1.2. Japan

            15.2.1.3. South Korea

        15.2.2. By Indication

        15.2.3. By Technology

        15.2.4. By Vaccine

        15.2.5. By End User

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Indication

        15.3.3. By Technology

        15.3.4. By Vaccine

        15.3.5. By End User

    15.4. Key Takeaways

16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. South Africa

            16.2.1.3. Israel

            16.2.1.4. Rest of MEA

        16.2.2. By Indication

        16.2.3. By Technology

        16.2.4. By Vaccine

        16.2.5. By End User

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Indication

        16.3.3. By Technology

        16.3.4. By Vaccine

        16.3.5. By End User

    16.4. Key Takeaways

17. Key Countries Market Analysis

    17.1. U.S.

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2022

            17.1.2.1. By Indication

            17.1.2.2. By Technology

            17.1.2.3. By Vaccine

            17.1.2.4. By End User

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2022

            17.2.2.1. By Indication

            17.2.2.2. By Technology

            17.2.2.3. By Vaccine

            17.2.2.4. By End User

    17.3. Brazil

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2022

            17.3.2.1. By Indication

            17.3.2.2. By Technology

            17.3.2.3. By Vaccine

            17.3.2.4. By End User

    17.4. Mexico

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2022

            17.4.2.1. By Indication

            17.4.2.2. By Technology

            17.4.2.3. By Vaccine

            17.4.2.4. By End User

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2022

            17.5.2.1. By Indication

            17.5.2.2. By Technology

            17.5.2.3. By Vaccine

            17.5.2.4. By End User

    17.6. U.K.

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2022

            17.6.2.1. By Indication

            17.6.2.2. By Technology

            17.6.2.3. By Vaccine

            17.6.2.4. By End User

    17.7. France

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2022

            17.7.2.1. By Indication

            17.7.2.2. By Technology

            17.7.2.3. By Vaccine

            17.7.2.4. By End User

    17.8. Spain

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2022

            17.8.2.1. By Indication

            17.8.2.2. By Technology

            17.8.2.3. By Vaccine

            17.8.2.4. By End User

    17.9. Italy

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2022

            17.9.2.1. By Indication

            17.9.2.2. By Technology

            17.9.2.3. By Vaccine

            17.9.2.4. By End User

    17.10. Poland

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2022

            17.10.2.1. By Indication

            17.10.2.2. By Technology

            17.10.2.3. By Vaccine

            17.10.2.4. By End User

    17.11. Russia

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2022

            17.11.2.1. By Indication

            17.11.2.2. By Technology

            17.11.2.3. By Vaccine

            17.11.2.4. By End User

    17.12. Czech Republic

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2022

            17.12.2.1. By Indication

            17.12.2.2. By Technology

            17.12.2.3. By Vaccine

            17.12.2.4. By End User

    17.13. Romania

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2022

            17.13.2.1. By Indication

            17.13.2.2. By Technology

            17.13.2.3. By Vaccine

            17.13.2.4. By End User

    17.14. India

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2022

            17.14.2.1. By Indication

            17.14.2.2. By Technology

            17.14.2.3. By Vaccine

            17.14.2.4. By End User

    17.15. Bangladesh

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2022

            17.15.2.1. By Indication

            17.15.2.2. By Technology

            17.15.2.3. By Vaccine

            17.15.2.4. By End User

    17.16. Australia

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2022

            17.16.2.1. By Indication

            17.16.2.2. By Technology

            17.16.2.3. By Vaccine

            17.16.2.4. By End User

    17.17. New Zealand

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2022

            17.17.2.1. By Indication

            17.17.2.2. By Technology

            17.17.2.3. By Vaccine

            17.17.2.4. By End User

    17.18. China

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2022

            17.18.2.1. By Indication

            17.18.2.2. By Technology

            17.18.2.3. By Vaccine

            17.18.2.4. By End User

    17.19. Japan

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2022

            17.19.2.1. By Indication

            17.19.2.2. By Technology

            17.19.2.3. By Vaccine

            17.19.2.4. By End User

    17.20. South Korea

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2022

            17.20.2.1. By Indication

            17.20.2.2. By Technology

            17.20.2.3. By Vaccine

            17.20.2.4. By End User

    17.21. GCC Countries

        17.21.1. Pricing Analysis

        17.21.2. Market Share Analysis, 2022

            17.21.2.1. By Indication

            17.21.2.2. By Technology

            17.21.2.3. By Vaccine

            17.21.2.4. By End User

    17.22. South Africa

        17.22.1. Pricing Analysis

        17.22.2. Market Share Analysis, 2022

            17.22.2.1. By Indication

            17.22.2.2. By Technology

            17.22.2.3. By Vaccine

            17.22.2.4. By End User

    17.23. Israel

        17.23.1. Pricing Analysis

        17.23.2. Market Share Analysis, 2022

            17.23.2.1. By Indication

            17.23.2.2. By Technology

            17.23.2.3. By Vaccine

            17.23.2.4. By End User

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Indication

        18.3.3. By Technology

        18.3.4. By Vaccine

        18.3.5. By End User

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. GlaxoSmithKline Plc.

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

                19.1.1.5.2. Product Strategy

                19.1.1.5.3. Channel Strategy

        19.1.2. Merck & Co. Inc

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

                19.1.2.5.2. Product Strategy

                19.1.2.5.3. Channel Strategy

        19.1.3. Pfizer Inc.

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

                19.1.3.5.2. Product Strategy

                19.1.3.5.3. Channel Strategy

        19.1.4. Sanofi SA

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

                19.1.4.5.2. Product Strategy

                19.1.4.5.3. Channel Strategy

        19.1.5. Panacea Biotec

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

                19.1.5.5.2. Product Strategy

                19.1.5.5.3. Channel Strategy

        19.1.6. Zydus Cadila

            19.1.6.1. Overview

            19.1.6.2. Product Portfolio

            19.1.6.3. Profitability by Market Segments

            19.1.6.4. Sales Footprint

            19.1.6.5. Strategy Overview

                19.1.6.5.1. Marketing Strategy

                19.1.6.5.2. Product Strategy

                19.1.6.5.3. Channel Strategy

        19.1.7. Emergent BioSolutions Inc

            19.1.7.1. Overview

            19.1.7.2. Product Portfolio

            19.1.7.3. Profitability by Market Segments

            19.1.7.4. Sales Footprint

            19.1.7.5. Strategy Overview

                19.1.7.5.1. Marketing Strategy

                19.1.7.5.2. Product Strategy

                19.1.7.5.3. Channel Strategy

        19.1.8. Serum Institute of India Pvt. Ltd.

            19.1.8.1. Overview

            19.1.8.2. Product Portfolio

            19.1.8.3. Profitability by Market Segments

            19.1.8.4. Sales Footprint

            19.1.8.5. Strategy Overview

                19.1.8.5.1. Marketing Strategy

                19.1.8.5.2. Product Strategy

                19.1.8.5.3. Channel Strategy

        19.1.9. Bharat Biotech and Indian Immunological

            19.1.9.1. Overview

            19.1.9.2. Product Portfolio

            19.1.9.3. Profitability by Market Segments

            19.1.9.4. Sales Footprint

            19.1.9.5. Strategy Overview

                19.1.9.5.1. Marketing Strategy

                19.1.9.5.2. Product Strategy

                19.1.9.5.3. Channel Strategy

        19.1.10. Catalent Inc

            19.1.10.1. Overview

            19.1.10.2. Product Portfolio

            19.1.10.3. Profitability by Market Segments

            19.1.10.4. Sales Footprint

            19.1.10.5. Strategy Overview

                19.1.10.5.1. Marketing Strategy

                19.1.10.5.2. Product Strategy

                19.1.10.5.3. Channel Strategy

        19.1.11. Robinson Pharma, Inc.

            19.1.11.1. Overview

            19.1.11.2. Product Portfolio

            19.1.11.3. Profitability by Market Segments

            19.1.11.4. Sales Footprint

            19.1.11.5. Strategy Overview

                19.1.11.5.1. Marketing Strategy

                19.1.11.5.2. Product Strategy

                19.1.11.5.3. Channel Strategy

        19.1.12. Hunan Er-Kang Pharmaceutical Co., Ltd.

            19.1.12.1. Overview

            19.1.12.2. Product Portfolio

            19.1.12.3. Profitability by Market Segments

            19.1.12.4. Sales Footprint

            19.1.12.5. Strategy Overview

                19.1.12.5.1. Marketing Strategy

                19.1.12.5.2. Product Strategy

                19.1.12.5.3. Channel Strategy

        19.1.13. Procaps

            19.1.13.1. Overview

            19.1.13.2. Product Portfolio

            19.1.13.3. Profitability by Market Segments

            19.1.13.4. Sales Footprint

            19.1.13.5. Strategy Overview

                19.1.13.5.1. Marketing Strategy

                19.1.13.5.2. Product Strategy

                19.1.13.5.3. Channel Strategy

        19.1.14. CAPTEK Softgel International Inc.

            19.1.14.1. Overview

            19.1.14.2. Product Portfolio

            19.1.14.3. Profitability by Market Segments

            19.1.14.4. Sales Footprint

            19.1.14.5. Strategy Overview

                19.1.14.5.1. Marketing Strategy

                19.1.14.5.2. Product Strategy

                19.1.14.5.3. Channel Strategy

        19.1.15. Softcaps, Fuji Capsule Co., Ltd.

            19.1.15.1. Overview

            19.1.15.2. Product Portfolio

            19.1.15.3. Profitability by Market Segments

            19.1.15.4. Sales Footprint

            19.1.15.5. Strategy Overview

                19.1.15.5.1. Marketing Strategy

                19.1.15.5.2. Product Strategy

                19.1.15.5.3. Channel Strategy

        19.1.16. Aenova Holding GmbH

            19.1.16.1. Overview

            19.1.16.2. Product Portfolio

            19.1.16.3. Profitability by Market Segments

            19.1.16.4. Sales Footprint

            19.1.16.5. Strategy Overview

                19.1.16.5.1. Marketing Strategy

                19.1.16.5.2. Product Strategy

                19.1.16.5.3. Channel Strategy

        19.1.17. Sirio Pharma Co., Ltd.

            19.1.17.1. Overview

            19.1.17.2. Product Portfolio

            19.1.17.3. Profitability by Market Segments

            19.1.17.4. Sales Footprint

            19.1.17.5. Strategy Overview

                19.1.17.5.1. Marketing Strategy

                19.1.17.5.2. Product Strategy

                19.1.17.5.3. Channel Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Volume (Units) Forecast by Region, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 4: Global Market Volume (Units) Forecast by Indication, 2018 to 2033

Table 5: Global Market Value (US$ Million) Forecast by Technology, 2018 to 2033

Table 6: Global Market Volume (Units) Forecast by Technology, 2018 to 2033

Table 7: Global Market Value (US$ Million) Forecast by Vaccine, 2018 to 2033

Table 8: Global Market Volume (Units) Forecast by Vaccine, 2018 to 2033

Table 9: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 10: Global Market Volume (Units) Forecast by End User, 2018 to 2033

Table 11: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 12: North America Market Volume (Units) Forecast by Country, 2018 to 2033

Table 13: North America Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 14: North America Market Volume (Units) Forecast by Indication, 2018 to 2033

Table 15: North America Market Value (US$ Million) Forecast by Technology, 2018 to 2033

Table 16: North America Market Volume (Units) Forecast by Technology, 2018 to 2033

Table 17: North America Market Value (US$ Million) Forecast by Vaccine, 2018 to 2033

Table 18: North America Market Volume (Units) Forecast by Vaccine, 2018 to 2033

Table 19: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 20: North America Market Volume (Units) Forecast by End User, 2018 to 2033

Table 21: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: Latin America Market Volume (Units) Forecast by Country, 2018 to 2033

Table 23: Latin America Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 24: Latin America Market Volume (Units) Forecast by Indication, 2018 to 2033

Table 25: Latin America Market Value (US$ Million) Forecast by Technology, 2018 to 2033

Table 26: Latin America Market Volume (Units) Forecast by Technology, 2018 to 2033

Table 27: Latin America Market Value (US$ Million) Forecast by Vaccine, 2018 to 2033

Table 28: Latin America Market Volume (Units) Forecast by Vaccine, 2018 to 2033

Table 29: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 30: Latin America Market Volume (Units) Forecast by End User, 2018 to 2033

Table 31: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 32: Western Europe Market Volume (Units) Forecast by Country, 2018 to 2033

Table 33: Western Europe Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 34: Western Europe Market Volume (Units) Forecast by Indication, 2018 to 2033

Table 35: Western Europe Market Value (US$ Million) Forecast by Technology, 2018 to 2033

Table 36: Western Europe Market Volume (Units) Forecast by Technology, 2018 to 2033

Table 37: Western Europe Market Value (US$ Million) Forecast by Vaccine, 2018 to 2033

Table 38: Western Europe Market Volume (Units) Forecast by Vaccine, 2018 to 2033

Table 39: Western Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 40: Western Europe Market Volume (Units) Forecast by End User, 2018 to 2033

Table 41: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 42: Eastern Europe Market Volume (Units) Forecast by Country, 2018 to 2033

Table 43: Eastern Europe Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 44: Eastern Europe Market Volume (Units) Forecast by Indication, 2018 to 2033

Table 45: Eastern Europe Market Value (US$ Million) Forecast by Technology, 2018 to 2033

Table 46: Eastern Europe Market Volume (Units) Forecast by Technology, 2018 to 2033

Table 47: Eastern Europe Market Value (US$ Million) Forecast by Vaccine, 2018 to 2033

Table 48: Eastern Europe Market Volume (Units) Forecast by Vaccine, 2018 to 2033

Table 49: Eastern Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 50: Eastern Europe Market Volume (Units) Forecast by End User, 2018 to 2033

Table 51: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 52: South Asia and Pacific Market Volume (Units) Forecast by Country, 2018 to 2033

Table 53: South Asia and Pacific Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 54: South Asia and Pacific Market Volume (Units) Forecast by Indication, 2018 to 2033

Table 55: South Asia and Pacific Market Value (US$ Million) Forecast by Technology, 2018 to 2033

Table 56: South Asia and Pacific Market Volume (Units) Forecast by Technology, 2018 to 2033

Table 57: South Asia and Pacific Market Value (US$ Million) Forecast by Vaccine, 2018 to 2033

Table 58: South Asia and Pacific Market Volume (Units) Forecast by Vaccine, 2018 to 2033

Table 59: South Asia and Pacific Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 60: South Asia and Pacific Market Volume (Units) Forecast by End User, 2018 to 2033

Table 61: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 62: East Asia Market Volume (Units) Forecast by Country, 2018 to 2033

Table 63: East Asia Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 64: East Asia Market Volume (Units) Forecast by Indication, 2018 to 2033

Table 65: East Asia Market Value (US$ Million) Forecast by Technology, 2018 to 2033

Table 66: East Asia Market Volume (Units) Forecast by Technology, 2018 to 2033

Table 67: East Asia Market Value (US$ Million) Forecast by Vaccine, 2018 to 2033

Table 68: East Asia Market Volume (Units) Forecast by Vaccine, 2018 to 2033

Table 69: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 70: East Asia Market Volume (Units) Forecast by End User, 2018 to 2033

Table 71: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 72: Middle East and Africa Market Volume (Units) Forecast by Country, 2018 to 2033

Table 73: Middle East and Africa Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 74: Middle East and Africa Market Volume (Units) Forecast by Indication, 2018 to 2033

Table 75: Middle East and Africa Market Value (US$ Million) Forecast by Technology, 2018 to 2033

Table 76: Middle East and Africa Market Volume (Units) Forecast by Technology, 2018 to 2033

Table 77: Middle East and Africa Market Value (US$ Million) Forecast by Vaccine, 2018 to 2033

Table 78: Middle East and Africa Market Volume (Units) Forecast by Vaccine, 2018 to 2033

Table 79: Middle East and Africa Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 80: Middle East and Africa Market Volume (Units) Forecast by End User, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Indication, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Technology, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Vaccine, 2023 to 2033

Figure 4: Global Market Value (US$ Million) by End User, 2023 to 2033

Figure 5: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 6: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 7: Global Market Volume (Units) Analysis by Region, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 11: Global Market Volume (Units) Analysis by Indication, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by Technology, 2018 to 2033

Figure 15: Global Market Volume (Units) Analysis by Technology, 2018 to 2033

Figure 16: Global Market Value Share (%) and BPS Analysis by Technology, 2023 to 2033

Figure 17: Global Market Y-o-Y Growth (%) Projections by Technology, 2023 to 2033

Figure 18: Global Market Value (US$ Million) Analysis by Vaccine, 2018 to 2033

Figure 19: Global Market Volume (Units) Analysis by Vaccine, 2018 to 2033

Figure 20: Global Market Value Share (%) and BPS Analysis by Vaccine, 2023 to 2033

Figure 21: Global Market Y-o-Y Growth (%) Projections by Vaccine, 2023 to 2033

Figure 22: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 23: Global Market Volume (Units) Analysis by End User, 2018 to 2033

Figure 24: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 25: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 26: Global Market Attractiveness by Indication, 2023 to 2033

Figure 27: Global Market Attractiveness by Technology, 2023 to 2033

Figure 28: Global Market Attractiveness by Vaccine, 2023 to 2033

Figure 29: Global Market Attractiveness by End User, 2023 to 2033

Figure 30: Global Market Attractiveness by Region, 2023 to 2033

Figure 31: North America Market Value (US$ Million) by Indication, 2023 to 2033

Figure 32: North America Market Value (US$ Million) by Technology, 2023 to 2033

Figure 33: North America Market Value (US$ Million) by Vaccine, 2023 to 2033

Figure 34: North America Market Value (US$ Million) by End User, 2023 to 2033

Figure 35: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 36: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 37: North America Market Volume (Units) Analysis by Country, 2018 to 2033

Figure 38: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 39: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 40: North America Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 41: North America Market Volume (Units) Analysis by Indication, 2018 to 2033

Figure 42: North America Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 43: North America Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 44: North America Market Value (US$ Million) Analysis by Technology, 2018 to 2033

Figure 45: North America Market Volume (Units) Analysis by Technology, 2018 to 2033

Figure 46: North America Market Value Share (%) and BPS Analysis by Technology, 2023 to 2033

Figure 47: North America Market Y-o-Y Growth (%) Projections by Technology, 2023 to 2033

Figure 48: North America Market Value (US$ Million) Analysis by Vaccine, 2018 to 2033

Figure 49: North America Market Volume (Units) Analysis by Vaccine, 2018 to 2033

Figure 50: North America Market Value Share (%) and BPS Analysis by Vaccine, 2023 to 2033

Figure 51: North America Market Y-o-Y Growth (%) Projections by Vaccine, 2023 to 2033

Figure 52: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 53: North America Market Volume (Units) Analysis by End User, 2018 to 2033

Figure 54: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 55: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 56: North America Market Attractiveness by Indication, 2023 to 2033

Figure 57: North America Market Attractiveness by Technology, 2023 to 2033

Figure 58: North America Market Attractiveness by Vaccine, 2023 to 2033

Figure 59: North America Market Attractiveness by End User, 2023 to 2033

Figure 60: North America Market Attractiveness by Country, 2023 to 2033

Figure 61: Latin America Market Value (US$ Million) by Indication, 2023 to 2033

Figure 62: Latin America Market Value (US$ Million) by Technology, 2023 to 2033

Figure 63: Latin America Market Value (US$ Million) by Vaccine, 2023 to 2033

Figure 64: Latin America Market Value (US$ Million) by End User, 2023 to 2033

Figure 65: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 66: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 67: Latin America Market Volume (Units) Analysis by Country, 2018 to 2033

Figure 68: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 69: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 70: Latin America Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 71: Latin America Market Volume (Units) Analysis by Indication, 2018 to 2033

Figure 72: Latin America Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 73: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 74: Latin America Market Value (US$ Million) Analysis by Technology, 2018 to 2033

Figure 75: Latin America Market Volume (Units) Analysis by Technology, 2018 to 2033

Figure 76: Latin America Market Value Share (%) and BPS Analysis by Technology, 2023 to 2033

Figure 77: Latin America Market Y-o-Y Growth (%) Projections by Technology, 2023 to 2033

Figure 78: Latin America Market Value (US$ Million) Analysis by Vaccine, 2018 to 2033

Figure 79: Latin America Market Volume (Units) Analysis by Vaccine, 2018 to 2033

Figure 80: Latin America Market Value Share (%) and BPS Analysis by Vaccine, 2023 to 2033

Figure 81: Latin America Market Y-o-Y Growth (%) Projections by Vaccine, 2023 to 2033

Figure 82: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 83: Latin America Market Volume (Units) Analysis by End User, 2018 to 2033

Figure 84: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 85: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 86: Latin America Market Attractiveness by Indication, 2023 to 2033

Figure 87: Latin America Market Attractiveness by Technology, 2023 to 2033

Figure 88: Latin America Market Attractiveness by Vaccine, 2023 to 2033

Figure 89: Latin America Market Attractiveness by End User, 2023 to 2033

Figure 90: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 91: Western Europe Market Value (US$ Million) by Indication, 2023 to 2033

Figure 92: Western Europe Market Value (US$ Million) by Technology, 2023 to 2033

Figure 93: Western Europe Market Value (US$ Million) by Vaccine, 2023 to 2033

Figure 94: Western Europe Market Value (US$ Million) by End User, 2023 to 2033

Figure 95: Western Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 96: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 97: Western Europe Market Volume (Units) Analysis by Country, 2018 to 2033

Figure 98: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 99: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 100: Western Europe Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 101: Western Europe Market Volume (Units) Analysis by Indication, 2018 to 2033

Figure 102: Western Europe Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 103: Western Europe Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 104: Western Europe Market Value (US$ Million) Analysis by Technology, 2018 to 2033

Figure 105: Western Europe Market Volume (Units) Analysis by Technology, 2018 to 2033

Figure 106: Western Europe Market Value Share (%) and BPS Analysis by Technology, 2023 to 2033

Figure 107: Western Europe Market Y-o-Y Growth (%) Projections by Technology, 2023 to 2033

Figure 108: Western Europe Market Value (US$ Million) Analysis by Vaccine, 2018 to 2033

Figure 109: Western Europe Market Volume (Units) Analysis by Vaccine, 2018 to 2033

Figure 110: Western Europe Market Value Share (%) and BPS Analysis by Vaccine, 2023 to 2033

Figure 111: Western Europe Market Y-o-Y Growth (%) Projections by Vaccine, 2023 to 2033

Figure 112: Western Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 113: Western Europe Market Volume (Units) Analysis by End User, 2018 to 2033

Figure 114: Western Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 115: Western Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 116: Western Europe Market Attractiveness by Indication, 2023 to 2033

Figure 117: Western Europe Market Attractiveness by Technology, 2023 to 2033

Figure 118: Western Europe Market Attractiveness by Vaccine, 2023 to 2033

Figure 119: Western Europe Market Attractiveness by End User, 2023 to 2033

Figure 120: Western Europe Market Attractiveness by Country, 2023 to 2033

Figure 121: Eastern Europe Market Value (US$ Million) by Indication, 2023 to 2033

Figure 122: Eastern Europe Market Value (US$ Million) by Technology, 2023 to 2033

Figure 123: Eastern Europe Market Value (US$ Million) by Vaccine, 2023 to 2033

Figure 124: Eastern Europe Market Value (US$ Million) by End User, 2023 to 2033

Figure 125: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 126: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 127: Eastern Europe Market Volume (Units) Analysis by Country, 2018 to 2033

Figure 128: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 129: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 130: Eastern Europe Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 131: Eastern Europe Market Volume (Units) Analysis by Indication, 2018 to 2033

Figure 132: Eastern Europe Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 133: Eastern Europe Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 134: Eastern Europe Market Value (US$ Million) Analysis by Technology, 2018 to 2033

Figure 135: Eastern Europe Market Volume (Units) Analysis by Technology, 2018 to 2033

Figure 136: Eastern Europe Market Value Share (%) and BPS Analysis by Technology, 2023 to 2033

Figure 137: Eastern Europe Market Y-o-Y Growth (%) Projections by Technology, 2023 to 2033

Figure 138: Eastern Europe Market Value (US$ Million) Analysis by Vaccine, 2018 to 2033

Figure 139: Eastern Europe Market Volume (Units) Analysis by Vaccine, 2018 to 2033

Figure 140: Eastern Europe Market Value Share (%) and BPS Analysis by Vaccine, 2023 to 2033

Figure 141: Eastern Europe Market Y-o-Y Growth (%) Projections by Vaccine, 2023 to 2033

Figure 142: Eastern Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 143: Eastern Europe Market Volume (Units) Analysis by End User, 2018 to 2033

Figure 144: Eastern Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 145: Eastern Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 146: Eastern Europe Market Attractiveness by Indication, 2023 to 2033

Figure 147: Eastern Europe Market Attractiveness by Technology, 2023 to 2033

Figure 148: Eastern Europe Market Attractiveness by Vaccine, 2023 to 2033

Figure 149: Eastern Europe Market Attractiveness by End User, 2023 to 2033

Figure 150: Eastern Europe Market Attractiveness by Country, 2023 to 2033

Figure 151: South Asia and Pacific Market Value (US$ Million) by Indication, 2023 to 2033

Figure 152: South Asia and Pacific Market Value (US$ Million) by Technology, 2023 to 2033

Figure 153: South Asia and Pacific Market Value (US$ Million) by Vaccine, 2023 to 2033

Figure 154: South Asia and Pacific Market Value (US$ Million) by End User, 2023 to 2033

Figure 155: South Asia and Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 156: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 157: South Asia and Pacific Market Volume (Units) Analysis by Country, 2018 to 2033

Figure 158: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 159: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 160: South Asia and Pacific Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 161: South Asia and Pacific Market Volume (Units) Analysis by Indication, 2018 to 2033

Figure 162: South Asia and Pacific Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 163: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 164: South Asia and Pacific Market Value (US$ Million) Analysis by Technology, 2018 to 2033

Figure 165: South Asia and Pacific Market Volume (Units) Analysis by Technology, 2018 to 2033

Figure 166: South Asia and Pacific Market Value Share (%) and BPS Analysis by Technology, 2023 to 2033

Figure 167: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Technology, 2023 to 2033

Figure 168: South Asia and Pacific Market Value (US$ Million) Analysis by Vaccine, 2018 to 2033

Figure 169: South Asia and Pacific Market Volume (Units) Analysis by Vaccine, 2018 to 2033

Figure 170: South Asia and Pacific Market Value Share (%) and BPS Analysis by Vaccine, 2023 to 2033

Figure 171: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Vaccine, 2023 to 2033

Figure 172: South Asia and Pacific Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 173: South Asia and Pacific Market Volume (Units) Analysis by End User, 2018 to 2033

Figure 174: South Asia and Pacific Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 175: South Asia and Pacific Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 176: South Asia and Pacific Market Attractiveness by Indication, 2023 to 2033

Figure 177: South Asia and Pacific Market Attractiveness by Technology, 2023 to 2033

Figure 178: South Asia and Pacific Market Attractiveness by Vaccine, 2023 to 2033

Figure 179: South Asia and Pacific Market Attractiveness by End User, 2023 to 2033

Figure 180: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033

Figure 181: East Asia Market Value (US$ Million) by Indication, 2023 to 2033

Figure 182: East Asia Market Value (US$ Million) by Technology, 2023 to 2033

Figure 183: East Asia Market Value (US$ Million) by Vaccine, 2023 to 2033

Figure 184: East Asia Market Value (US$ Million) by End User, 2023 to 2033

Figure 185: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 186: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 187: East Asia Market Volume (Units) Analysis by Country, 2018 to 2033

Figure 188: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 189: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 190: East Asia Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 191: East Asia Market Volume (Units) Analysis by Indication, 2018 to 2033

Figure 192: East Asia Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 193: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 194: East Asia Market Value (US$ Million) Analysis by Technology, 2018 to 2033

Figure 195: East Asia Market Volume (Units) Analysis by Technology, 2018 to 2033

Figure 196: East Asia Market Value Share (%) and BPS Analysis by Technology, 2023 to 2033

Figure 197: East Asia Market Y-o-Y Growth (%) Projections by Technology, 2023 to 2033

Figure 198: East Asia Market Value (US$ Million) Analysis by Vaccine, 2018 to 2033

Figure 199: East Asia Market Volume (Units) Analysis by Vaccine, 2018 to 2033

Figure 200: East Asia Market Value Share (%) and BPS Analysis by Vaccine, 2023 to 2033

Figure 201: East Asia Market Y-o-Y Growth (%) Projections by Vaccine, 2023 to 2033

Figure 202: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 203: East Asia Market Volume (Units) Analysis by End User, 2018 to 2033

Figure 204: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 205: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 206: East Asia Market Attractiveness by Indication, 2023 to 2033

Figure 207: East Asia Market Attractiveness by Technology, 2023 to 2033

Figure 208: East Asia Market Attractiveness by Vaccine, 2023 to 2033

Figure 209: East Asia Market Attractiveness by End User, 2023 to 2033

Figure 210: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 211: Middle East and Africa Market Value (US$ Million) by Indication, 2023 to 2033

Figure 212: Middle East and Africa Market Value (US$ Million) by Technology, 2023 to 2033

Figure 213: Middle East and Africa Market Value (US$ Million) by Vaccine, 2023 to 2033

Figure 214: Middle East and Africa Market Value (US$ Million) by End User, 2023 to 2033

Figure 215: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033

Figure 216: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 217: Middle East and Africa Market Volume (Units) Analysis by Country, 2018 to 2033

Figure 218: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 219: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 220: Middle East and Africa Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 221: Middle East and Africa Market Volume (Units) Analysis by Indication, 2018 to 2033

Figure 222: Middle East and Africa Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 223: Middle East and Africa Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 224: Middle East and Africa Market Value (US$ Million) Analysis by Technology, 2018 to 2033

Figure 225: Middle East and Africa Market Volume (Units) Analysis by Technology, 2018 to 2033

Figure 226: Middle East and Africa Market Value Share (%) and BPS Analysis by Technology, 2023 to 2033

Figure 227: Middle East and Africa Market Y-o-Y Growth (%) Projections by Technology, 2023 to 2033

Figure 228: Middle East and Africa Market Value (US$ Million) Analysis by Vaccine, 2018 to 2033

Figure 229: Middle East and Africa Market Volume (Units) Analysis by Vaccine, 2018 to 2033

Figure 230: Middle East and Africa Market Value Share (%) and BPS Analysis by Vaccine, 2023 to 2033

Figure 231: Middle East and Africa Market Y-o-Y Growth (%) Projections by Vaccine, 2023 to 2033

Figure 232: Middle East and Africa Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 233: Middle East and Africa Market Volume (Units) Analysis by End User, 2018 to 2033

Figure 234: Middle East and Africa Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 235: Middle East and Africa Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 236: Middle East and Africa Market Attractiveness by Indication, 2023 to 2033

Figure 237: Middle East and Africa Market Attractiveness by Technology, 2023 to 2033

Figure 238: Middle East and Africa Market Attractiveness by Vaccine, 2023 to 2033

Figure 239: Middle East and Africa Market Attractiveness by End User, 2023 to 2033

Figure 240: Middle East and Africa Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Vaccines Market

Published : January 2023

Healthcare

Pneumococcal Vaccines Market

Published : December 2022

Healthcare

Attenuated Vaccines Market

Published : May 2022

Explore Healthcare Insights

View Reports

Paediatric Vaccine Market